Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 17/2010

01.12.2010 | Adis Drug Profile

Indacaterol

In Chronic Obstructive Pulmonary Disease

verfasst von: Marit D. Moen

Erschienen in: Drugs | Ausgabe 17/2010

Einloggen, um Zugang zu erhalten

Abstract

Indacaterol is a long-acting β2-adrenoceptor agonist that is available in the EU for the maintenance treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Indacaterol has a 24-hour bronchodilatory effect, which allows for once-daily administration. The onset of bronchodilation after inhalation of indacaterol is fast, with significant improvements versus placebo seen 5 minutes after inhalation.
In four large (n > 400), randomized, double-blind, placebo-controlled, multicentre phase III trials, patients with COPD who received indacaterol 150 or 300 μg once daily had a significantly higher mean trough forced expiratory volume in 1 second (FEV1) than placebo recipients after 12 weeks.
Trough FEV1 differences between indacaterol and placebo recipients were 130–180 mL and exceeded the clinically relevant threshold of 120 mL in all trials. Furthermore, indacaterol recipients had significantly higher mean trough FEV1 values after 12 weeks than patients who received formoterol, salmeterol or open-label tiotropium.
COPD exacerbations and symptoms, and health-related quality of life were also significantly improved for indacaterol versus placebo recipients in some studies.
Indacaterol was generally well tolerated by adults with moderate to severe COPD.
Literatur
1.
2.
Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006 Sep; 28(3): 523–32PubMedCrossRef
3.
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 Aug 15; 178(4): 332–8PubMedCrossRef
4.
Onbrez Breezhaler (indacaterol) 150 and 300 microgram inhalation powder, hard capsules: EU summary of product characteristics. West Sussex, UK: Novartis Europharm Limited, 2009
5.
Scola AM, Loxham M, Charlton SJ, et al. The long-acting β-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol 2009; 158: 267–76PubMedCrossRef
6.
Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydro xy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006 May; 317(2): 762–70PubMedCrossRef
7.
Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi. Eur Respir J 2007 Mar; 29(3): 575–81PubMedCrossRef
8.
Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled β2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008 Jan; 324(1): 270–5PubMedCrossRef
9.
Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009 Dec 8; 38(5): 533–47PubMedCrossRef
10.
Rosethorne EM, Turner RJ, Fairhurst RA, et al. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled β2-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 2010 Sep; 382(3): 255–63PubMedCrossRef
11.
Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract 2006 Apr; 60(4): 415–21PubMedCrossRef
12.
Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol 2006 Oct–Dec; 31(2–3): 181–96PubMedCrossRef
13.
Rider NL, Craig TJ. A safety review of long-acting β2-agonists in patients with asthma. J Am Osteopath Assoc 2006 Sep; 106(9): 562–7PubMed
14.
Matera MG, Cazzola M. Ultra-long-acting β2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 2007; 67(4): 503–15PubMedCrossRef
15.
Battram C, Li J, Coulthard A, et al. Indacaterol does not blunt the effect of salbutamol in vivo [abstract no. A2075]. Am J Respir Crit Care Med 2009; 179
16.
Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008 Jul; 102(7): 1033–44PubMedCrossRef
17.
Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009 Feb; 25(2): 463–70PubMedCrossRef
18.
Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11PubMedCrossRef
19.
Beier J, Beeh K-M, Brookman L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009 Dec; 22(6): 492–6PubMedCrossRef
20.
LaForce C, Aumann J, de Teresa Parreño L, et al. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther. Epub 2010 Jul 7
21.
Beier J, Chanez P, Martinot J-B, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007; 20(6): 740–9PubMedCrossRef
22.
Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010 Oct 5; 11(1): 135PubMedCrossRef
23.
Balint B, Watz H, Amos C, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010; 5: 311–8PubMed
24.
Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med. Epub 2010 Sep 16
25.
O’Donnell DE, Casaburi R, Swales J, et al. Effect of indacaterol on exercise endurance in patients with moderate-to-severe COPD [abstract no. F68]. Am J Respir Crit Care Med 2010; 181: A4431
26.
Beeh K-M, Khindri S, Eeg M, et al. Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD [abstract no. E4357]. 19th Annual Congress of the European Respiratory Society; 2009 Sep 12–16; Vienna
27.
Cazzola M, Matera MG, Donner CF. Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65(12): 1595–610PubMedCrossRef
28.
Beier J, Bantje T, Owen R, et al. Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD [abstract no. P3611]. Eur Respir J 2008 Oct; 32 Suppl. 52: 631s
29.
Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol — no clinical effect on QT in healthy subjects [abstract no. P2031]. 19th Annual Congress of the European Respiratory Society; 2009 Sep 12–16; Vienna
30.
Perry S, Woessner R, Kaiser G, et al. Pharmacokinetics of indacaterol after single and multiple inhaled doses [abstract no. F57]. Am J Respir Crit Care Med 2010; 181: A4420. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14–19; New Orleans (LA)
31.
32.
Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182(2): 155–62PubMedCrossRef
33.
Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010 Jun; 65(6): 473–9PubMedCrossRef
34.
Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. Epub 2010 Aug 6
35.
Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol: a 12-week trial [abstract plus poster]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18–22; Barcelona
36.
Novartis clinical trial results database. A 12 week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 μg o.d.) via a SDDPI in patients with moderate to severe COPD, using salmeterol (50 μg b.i.d.) as an active comparator delivered via a DISKUS inhaler [online]. Available from URL: http://​www.​novctrd.​com [Accessed 2010 Oct 13]
37.
Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010 Jun; 23(3): 165–71PubMedCrossRef
38.
Rennard SI, Chapman KR, Luthra A, et al. Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [abstract]. 75th Annual Meeting of the American College of Chest Physicians; 2009 Oct 31–Nov 5; San Diego (CA)
39.
Mahler DA, Buhl R, Owen R, et al. Indacaterol provides effective bronchodilation in patients with chronic obstructive pulmonary disease irrespective of patient age (<65 or ≥65 years) [abstract no. F93]. Am J Respir Crit Care Med 2010; 181: A4456. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14–19; New Orleans (LA)
40.
Donohue JF, Decramer M, Owen R, et al. Indacaterol provides significant bronchodilation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use [abstract no. F75]. Am J Respir Crit Care Med 2010; 181: A4438. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14–19; New Orleans (LA)
41.
Kleerup EC, D’Urzo A, Owen R, et al. Once-daily indacaterol provides significant bronchodilation in chronic obstructive pulmonary disease patients irrespective of baseline reversibility [abstract no. F76]. Am J Respir Crit Care Med 2010; 181: A4439. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14–19; New Orleans (LA)
42.
Siler TM, Williams J, Yegen U, et al. The effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med 2010; 181: A4430. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14–19; New Orleans (LA)
43.
Kleerup E, Williams J, Yegen U, et al. The effect of indacaterol once-daily on health-related quality of life, symptoms and rescue medication use in moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of six month data [abstract no. F66]. Am J Respir Crit Care Med 2010; 181: A4429. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14–19; New Orleans (LA)
44.
Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008 Oct; 155(3): 291–9PubMedCrossRef
45.
Roig J, Hernando R, Mora R. Indacaterol, a novel once daily inhaled β2-adrenoreceptor agonist. Open Respir Med J 2009; 3: 27–30PubMedCrossRef
Metadaten
Titel
Indacaterol
In Chronic Obstructive Pulmonary Disease
verfasst von
Marit D. Moen
Publikationsdatum
01.12.2010
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 17/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11203960-000000000-00000

Weitere Artikel der Ausgabe 17/2010

Drugs 17/2010 Zur Ausgabe

Leading Article

Drugs in Development for Tuberculosis

Review Article

Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus

Adis Drug Profile

Fentanyl Sublingual

Adis Drug Evaluation

Olanzapine Long-Acting Injection

Adis Drug Evaluation

Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®)

Review Article

Triple-Negative Breast Cancer